Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroectodermal Tumors, Primitive 2Neuroendocrine Tumors 1Kidney Neoplasms 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

antineoplaston AS 2-1 3antineoplaston A10 3dactolisib 2Temozolomide 2Irinotecan 2Everolimus 2Bevacizumab 2surufatinib 1spartalizumab 1poly ICLC 1plerixafor 1pasireotide 1fosbretabulin 1cixutumumab 1adavosertib 1Vaccines 1TH 302 1Sunitinib 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1PM 00104 1Lapatinib 1Immunologic Techniques 1Immunoglobulin G 1Genistein 1Fentanyl 1Donepezil 1Disulfides 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive × dactolisib × Clear all
NCT01658436 2016-05-02

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Novartis

Phase 2 Completed
31 enrolled 7 charts

Neuroectodermal Tumors, Primitive

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡